ArtemiLife, the company responsible for developing ArtemiCafé® Decaf, is currently conducting a Phase 2 trial at the University of Kentucky Markey Cancer Center, which is nearing its completion. This decaffeinated coffee product is infused with a precise dose of certain ingredients. This information was released on April 6, 2026, from CAMP HILL, Pa. The specific details regarding the trial's progress and outcomes, including significant data and results, were not disclosed in the provided information.